Log In Get Started
Press Releases April 1, 2026 08:00 PM

RxSight, Inc. to Participate in the 25th Annual Needham Virtual Healthcare Conference

RxSight to Participate in the 25th Annual Needham Virtual Healthcare Conference with Management Fireside Chat Scheduled

By Jordan Park
Share
Twitter Reddit Facebook LinkedIn
RXST

RxSight, Inc., a company specializing in ophthalmic medical devices, announced its participation in the 25th Annual Needham Virtual Healthcare Conference, featuring a management fireside chat on April 16, 2026. The company highlights its innovative Light Adjustable Lens system that allows post-surgery vision customization for cataract patients.

RxSight, Inc. to Participate in the 25th Annual Needham Virtual Healthcare Conference
RXST
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • RxSight will present at the Needham Virtual Healthcare Conference on April 16, 2026.
  • The company’s Light Adjustable Lens system is the first adjustable intraocular lens technology available commercially.
  • The participation will include a live and archived webcast accessible via the company’s investor relations website.
  • The ophthalmic medical devices sector and healthcare technology markets may be influenced by RxSight’s innovation exposure.

ALISO VIEJO, Calif., April 02, 2026 (GLOBE NEWSWIRE) -- (NASDAQ: RXST) RxSight, Inc., today announced plans to participate in the upcoming 25th Annual Needham Virtual Healthcare Conference. Management is scheduled to participate in a fireside chat on Thursday, April 16, 2026, at 8:00 a.m. Pacific Time. A live and archived webcast of the presentation will be available on the company’s investor relations website at https://investors.rxsight.com/.

About RxSight, Inc.

RxSight, Inc. is an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery. The RxSight® Light Adjustable Lens system, comprised of the RxSight Light Adjustable Lens® (LAL®/LAL+®, collectively the “LAL”), RxSight Light Delivery Device (LDD™) and accessories, is the first and only commercially available intraocular lens (IOL) technology that can be adjusted after surgery, enabling doctors to customize and deliver high-quality vision to patients after cataract surgery. Additional information about RxSight can be found at www.rxsight.com.

Investor Relations Contact:
Oliver Moravcevic
VP, Investor Relations
[email protected]


Risks

  • Market adoption of the Light Adjustable Lens system may be slower than expected, limiting revenue growth.
  • Competition in the ophthalmic medical device industry could impact RxSight’s market share and profitability.
  • Regulatory changes or challenges could affect the approval and commercialization of their intraocular lens technology.

More from Press Releases

Rhythm Pharmaceuticals Presents Positive Interim Six-month Data from Phase 2 Trial of Setmelanotide in Patients with Prader-Willi Syndrome (PWS) at ENDO 2026 Jun 13, 2026 Intellia Therapeutics Reports Additional Positive Phase 3 Results for Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema Jun 13, 2026 Arcadia Biosciences (RKDA) Announces Closing of $4 Million Private Placement Priced At-The-Market Under Nasdaq Rules Jun 12, 2026 Belite Bio Completes Rolling Submission of New Drug Application to U.S. Food and Drug Administration for Tinlarebant for the Treatment of Stargardt Disease Type 1 Jun 12, 2026 ROMA Green Finance Establishes Dedicated Artificial Intelligence and High-Performance Computing Infrastructure Investment Vertical Jun 12, 2026